Keywords targeted therapy cell state monocytic progenitor Introduction In recent years, initial remission rates for elderly patients with acute myeloid leukemia (AML) have seen improvement due to the combination therapy of the BCL2 inhibitor venetoclax (ven) with hypomethylating agents azacitidine (aza) and decitabine.1,2 However, drug resistance and disease relapse continue to be major hurdles in the long-term management and overall survival of patients with AML due to the heterogeneity of...
Andy Kaempf
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Andy
Contact Andy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack